Inhibition of the Sterol Regulatory Element Binding Protein SREBF-1 Overcomes Docetaxel Resistance in Advanced Prostate Cancer
-
Published:2024-08
Issue:
Volume:
Page:
-
ISSN:0002-9440
-
Container-title:The American Journal of Pathology
-
language:en
-
Short-container-title:The American Journal of Pathology
Author:
Brandt Maximilian PeterORCID,
Vakhrusheva Olesya,
Hackl HubertORCID,
Daher Tamas,
Tagscherer Katrin,
Roth Wilfried,
Tsaur Igor,
Handle FlorianORCID,
Eigentler AndreaORCID,
Culig ZoranORCID,
Thomas Christian,
Erb Holger H.H.ORCID,
Haferkamp Axel,
Jüngel Eva,
Puhr MartinORCID
Reference55 articles.
1. Apalutamide treatment and metastasis-free survival in prostate cancer;Smith;N Engl J Med,2018
2. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study;Fizazi;Lancet Oncol,2012
3. Darolutamide in nonmetastatic, castration-resistant prostate cancer;Fizazi;N Engl J Med,2019
4. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N Engl J Med,2017
5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016